NOUL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,040 KRW | +3.05% |
|
+6.85% | -25.12% |
| Apr. 25 | Noul Announces 2 Clinical Performance Studies At Pan-African Malaria Conference | CI |
| 2023 | Noul Co., Ltd. Unveils the Result of Malaria Study in Ethiopia and Ghana | CI |
| Sales 2022 | 541.88 749K | Sales 2023 | 2.73K 3.78M | Capitalization | 150B 207,283B |
|---|---|---|---|---|---|
| Net income 2022 | -13.68B -18,904B | Net income 2023 | -16.32B -22,553B | EV / Sales 2022 | 182,034,830 x |
| Net Debt 2022 | 140M 194B | Net cash position 2023 | 11.81B 16,322B | EV / Sales 2023 | 50,549,049 x |
| P/E ratio 2022 |
-6.92
x | P/E ratio 2023 |
-6.66
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 68.44% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.05% | ||
| 1 week | +6.85% | ||
| Current month | +6.85% | ||
| 1 month | +20.16% | ||
| 3 months | +2.18% | ||
| 6 months | -41.31% | ||
| Current year | -25.12% |
1 week
2 840.00
3 085.00
1 month
2 470.003 085.00
Current year
2 040.004 105.00
1 year
1 987.508 520.00
3 years
1 987.508 520.00
5 years
1 987.508 520.00
10 years
1 987.508 520.00
| Managers | Title | Age | Since |
|---|---|---|---|
Chan-Young Im
CEO | Chief Executive Officer | 45 | 15-11-30 |
Ri-Hyeon Kim
DFI | Director of Finance/CFO | 42 | 20-04-30 |
Dong-Young Lee
CTO | Chief Tech/Sci/R&D Officer | 45 | 15-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chan-Young Im
CEO | Chief Executive Officer | 45 | 15-11-30 |
Dong-Young Lee
CTO | Chief Tech/Sci/R&D Officer | 45 | 15-11-30 |
Kyung-Hwan Kim
BRD | Director/Board Member | 45 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 3,040 | +3.05% | 502,323 |
| 24-06-13 | 2,950 | -2.16% | 719,367 |
| 24-06-12 | 3,015 | -0.17% | 302,182 |
| 24-06-11 | 3,020 | +2.20% | 554,580 |
| 24-06-10 | 2,955 | +3.87% | 828,529 |
End-of-day quote Korea S.E., June 13, 2024
More quotes
Noul Co Ltd is a Korea-based company principally engaged in the next generation diagnostic testing platform business. The Company is engaged in the manufacture and sale of blood test diagnostic devices based on the artificial intelligence (AI) algorithms and diagnostic kits. In addition, the Company is also engaged in the provision of services such as regular monthly subscriptions and others through an integrated web-based remote diagnosis system.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -25.12% | 81.16M | |
| -43.39% | 7.73B | |
| +11.68% | 3.7B | |
| -21.21% | 1.99B | |
| -23.77% | 1.6B | |
| +14.81% | 999M | |
| +18.25% | 739M | |
| -10.04% | 685M | |
| -36.12% | 461M | |
| -4.47% | 279M |
- Stock Market
- Equities
- A376930 Stock
